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Effects of topical 2% cyclosporine A on the corneas of dogs subjected to lamellar
keratoplasty with a graft of equine pericardium preserved in glycerin.
Clinical and morphological evaluation
ABSTRACT
The effects of topical 2% cyclosporine A on the
cornea of dogs subjected to experimental lamellar
keratoplasty with an equine pericardial graft were evaluated.
Ten dogs were grouped to be evaluated 3, 7, 15, 30 and 60
days after surgery. Animals received bilateral grafts followed
by the application of a 2% cyclosporine A ointment on the
left eye (treated eye)  and the ointment base on the right eye
(control eye) twice a day. The ophthalmic evaluation showed
profound bilateral blepharospasm, photophobia and a
mucous secretion until the 7th day after surgery; corneal
vascularization starting in the limbus was observed as early
as the 3rd day in both eyes; opacification and vascularization
were more intense in the treated cornea on days 15 and 30
after surgery. Vascularization was still evident on the 60th
day, and looked similar in treated eyes and control eyes. The
histologic evaluation showed a complete bilateral
reepithelization and corneal vascularization three days after
the surgery; intense vascularization in both eyes on days 15
and 30, that was much more pronounced in the treated
cornea; and a bilateral predominance of
polymorphonuclear cells until day 15, and mononuclear
cells on day 30. Intact epithelium and stroma with new
vessels, as well as graft absorption, in both eyes, were seen
on the 60th day. The lamellar keratoplasty with equine
pericardial graft was an effective model to study the
inflammatory kinetics and corneal vascularization
phenomenon. In this study, cyclosporine A did not inhibit
corneal vascularization and it did not interfere in the corneal
cicatricial process.
Key words:  cyclosporine, cornea, pericardium,
vascularization, keratoplasty, dogs.
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RESUMO
Foram avaliados os efeitos da ciclosporina A a
2% sobre a córnea de cães submetidos à ceratoplastia lamelar
experimental com implante de pericárdio de equino. Dez
cães foram divididos em grupos para estudo aos três, sete,
15, 30 e 60 dias de pós-operatório, recebendo implantes
bilaterais e em seguida aplicação da pomada com
ciclosporina A a 2% no olho esquerdo (olho tratado)e
somente a base da mesma pomada no olho direito (olho
controle), duas vezes ao dia. À avaliação oftalmológica
observou-se, bilateralmente, blefarospasmo, fotofobia e
secreção mucosa evidentes até 7 dias de pós-operatório; início
de vascularização a partir do limbo aos três dias,
bilateralmente; opacidade e vascularização mais intensos
em córnea esquerda aos 15 e 30 dias; vascularização ainda
evidente, bilateralmente, com aspecto semelhante aos 60 dias.
À avaliação histopatológica observou-se, bilateralmente,
completa reepitelização e vascularização aos três dias de
pós-operatório; vascularização intensa aos 15 e 30 dias,
bilateralmente, porém acentuada na córnea esquerda;
predomínio de polimorfonucleares até os 15 dias e
mononucleares aos 30 dias, bilateralmente; epitélio e estroma
íntegros com vasos ainda evidentes e implante incorporado
ao estroma, bilateralmente, aos 60 dias. A utilização do
implante de pericárdio de equino em ceratoplastias lamelares
em cães constitui uma técnica eficaz, aplicável ao estudo da
cinética inflamatória e fenômeno de vascularização. A
ciclosporina A a 2% não inibiu ou diminuiu a formação
vascular na córnea e também não interferiu no processo
cicatricial neste estudo.
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INTRODUCTION
 Corneal ulceration is very frequent and
represents one of the most important eye diseases in
veterinary ophthalmology. It requires quick
intervention, even in the most superficial lesions, in
order to avoid serious complications and preserve the
vision (BROOKS, 2000).  Many therapeutic attempts
have been made over the years to repair the cornea in
order to maintain its structure and, if possible, its
transparency and function. Surgical therapeutic
methods are very important in corneal ulcer cases with
important corneal tissue loss, in which the only
alternative is tissue substitution (BARROS et al., 1995).
Equine pericardium was successfully used
in the correction of entropion and to fill the orbital
cavity of dog following enucleation (BARROS et al.,
1985) , as well as in the repair of the sclera and third
eyelid in dogs (BARROS et al., 1990). In cases of
penetrating sclerokeratectomy due to limbal neoplasia
(BARROS et al., 1995); keratectomy with partial
iridectomy due to a perforating lesion (BARROS et al.,
1995) and in lamellar and penetrating keratoplasty in
dogs, it was also effective because of the perfect
integration between the pericardium and the cornea
and the absence of rejection phenomena (KAVINSKI,
1980; BARROS et al., 1995; BARROS et al., 1997).
Although the results are good with the use of
pericardium for the anatomic preservation of frail or
perforated cornea, the occurrence of cicatricial reaction
with leucoma and corneal vascularization may be a
limiting factor  to its use, especially in axial or extensive
wounds, for vision may be affected.
The present trial was performed in order to
evaluate the lamellar keratoplasty with an equine
pericardial graft preserved in glycerin and the effects
of topic cyclosporine A on these corneas of dogs,
because it does not interfere in the cicatricial process
of the cornea (READ, 1996); because of its potential
for decreasing corneal vascularization (EPSTEIN et al.,
1987; LIPMAN et al., 1992; NORRBY, 1992; BENELLI
et al., 1997) and because of the beneficial results
observed using topical cyclosporine A on several
corneal inflammatory affections (KASWAN et al., 1989;
JACKSON et al., 1991; MORGAN & ABRAMS, 1991;
READ, 1996; STEVENSON et al., 2000).
MATERIALS  AND  METHODS
All animals involved in this study were
maintained and handled in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research. Ten mixed-breed male dogs, weighing
around 15kg were divided in five groups of two dogs
each  to be studied after 3, 7, 15, 30 and 60 days of the
surgery. Preoperative ophthalmic examination included
slit-lamp biomicroscopy, fluorescein strip test,
Schirmer tear test, TonoPen applanation tonometry and
direct ophthalmoscopy. The anesthetic protocol
included premedication using intramuscular 0,2mg.kg-1
of 0,2% acepromazine; induction using intravenous
12,5mg.kg-1 of Tiopental; and maintenance using 1,0-
2,5% of halothane in semiclosed circle rebreathing
system.
A corneal wound in the upper temporal area
of each cornea was produced using a  5mm trephine.
The lesion involved the epithelium and approximately
half of the width of the stroma. A 5mm diameter patch
of pericardium preserved in 98% glycerin, previously
hydrated using saline solution, was placed on the
wound and sutured in the corneal defect in a single
interrupted pattern using 8-0 nylon sutures. These
procedures were first performed in the right eye, and
then in the left eye of each animal.
As an immediate post-surgical procedure,
a 2% cyclosporine A ointment* was applied to the left
eye (treated eye) and only the base of the ointment*
to the right eye (control eye), twice a day, until the end
of the evaluation period. No other topical or sistemic
drug was used during these periods.
The animals were submitted to ophthalmic
examination with slit-lamp biomicroscopy daily, in
which parameters such as blepharospasm,
photophobia, ocular secretion, corneal opacification,
corneal vascularization and pigmentation were
analyzed. Viability, permanence and transparency of
the grafts were also observed. These parameters were
classified as absent, minor, moderate, intense and major.
At the end of the period of study, animals were
euthanized and their eyes enucleated and fixed in a
10% buffered formaldehyde solution. Sections were
stained by H & E, PAS and Masson’s trichrome stain,
and examined by light microscopy.  Aspects such as
reepithelization, edema, corneal vascularization and
polymorphonuclear and mononuclear leukocyte
infiltration were analyzed.
RESULTS
Clinical aspects
Blepharospasm and photophobia were
observed in all animals, and were intense up to the 7th
postoperative day; they were minor on day 15 and
bilaterally absent from the 30th day on. In relation to
the quali-quantitative evaluation of secretion, it was
observed a bilateral predominance of serum-mucous
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type, evident from the 3rd to 15th postoperative day,
and  absent  in  the  other  observation periods, being
moderate on the 7th day.
In relation to corneal opacification, it was
minor adjacent to the graft on the 7th postoperative
day;
moderate in the control cornea (Fig.1A), and
intense in the treated cornea on day 15 (Fig.1B). It was
still present bilaterally on day 30 (Figs.1C and D), and
it was reduced on the 60th postoperative day. A leucoma
in the graft area was similar in both corneas.
Corneal vascular formation began at the
limbus of the upper temporal region bilaterally on the
3rd postoperative day; it was more evident bilaterally
on day 7, intense in the control cornea (Fig.1A), and
major, reaching the graft, in the treated cornea on day
15 (Fig.1B);  it was also intense bilaterally on day 30
(Figs.1C and D); however, it was still prominent in the
treated cornea  (Fig. 1D). The appearance of both
corneas was similar on the 60th postoperative day, when
corneal vessels, some suture granulomas, and excellent
transparency of the cornea and partial transparency
of the implant were observed. None of the corneas
presented pigmentation.
Histopathologic findings
Complete bilateral reepithelization was
observed on the 3rd postoperative day, with the
presence of regenerative phase epithelium, and
acanthosis in the transition cornea/graft. On day 7,
the basal layer of the epithelium was starting to be
defined, and on day 15 it was stratified, presenting
almost normal width. The stroma had fibroblastic
hypertrophy with an increase in the collagenous matrix
and bilateral inflammatory infiltrate with predominance
of polymorphonuclear cells. On day 30, the epithelium
presented bilaterally several polyedrical and
cylindrical layers (Figs.2A and B), and complete
Figure 1 – A) Control cornea at day 15: mild vascularization and light edema close to the implant; B) Treated cornea at day 15: heavy
vascularization and strong edema at the implante site.
C) Control cornea at day 30: intense vascularization surrounding the implant; D) Treated cornea at day 30: intense vascularization over
and surrouding the implant, discret opacification close to the implant, exuberant granulation.
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regeneration occurred  by the 60th postoperative day
when remains of the graft were observed among the
reconstituted stroma suggesting an absorption
process.
Edema adjacent to the graft was observed
bilaterally on the 7th postoperative day, and was more
evident on day 15 when disarrangement of the lamellae
of the stroma with presence of fibroblasts and
inflammatory cells could be observed. There was an
increase in the width of the cornea in the keratoplasty
site when compared to the intact cornea. In this phase,
epithelial edema was also observed, and it was
characterized by vacuolization which was also evident
on the 30th postoperative day. These events
disappeared on day 60.
Corneal vascular formation occurred
associated with the inflammatory events, and vessels
were observed bilaterally from the limbus towards
the keratoplasty site on the 3rd postoperative day.
On day 7, these vessels took up most of the stroma,
bilaterally. On day 15, the phenomenon was intense
in both corneas, with vessels in the interface graft/
stroma, inside the graft and in the adjacent stroma.
On day 30, vascularization was still intense bilaterally
with vessels inside the graft and in the adjacent
stroma (Figs.2A and B). The vessels, however, took
a greater part of the stroma of the treated corneas of
the animals in this group (Fig.2B). On the 60th
postoperative day, vessels were still present in similar
amount bilaterally.
Inflammatory cell infiltrate was
characterized, bilaterally, by the early infiltration of
polymorphonuclear cells in the adjacent stroma, in the
interface and inside the graft. It was present up to the
15th postoperative day associated with the intense
vascularization in this phase. A major inflammatory
setting was observed, with intra-epithelial
inflammation in the treated cornea of the animals of
the 15th day group. On day 30, a chronic inflammatory
reaction was observed with the bilateral presence of
mononuclear cells and rare polymorphonuclear cells
in the adjacent stroma and inside the graft (Figs. 2A
and B). On day 60, a discrete mononuclear cell infiltrate
was observed  in the corneal  stroma bilaterally.
DISCUSSION
Photophobia and blepharospasm were
evident immediately after the surgery and  occurred
due to stimulation of the sensors epithelium and stroma
nerve terminations  (WARING, 1984)  produced by the
surgical procedure and the presence of the graft, as
well as the contact of the sutures with the eyelid
conjuntiva. This is a frequent finding in keratoplasties
with lamellar and penetrating grafts, in which there is
no burying of the suture knots.  Secretion was
predominantly mucous, which is present in
conjunctival and corneal processes, due to the
stimulation of caliciform cells; it was, therefore,
expected in such a surgical procedure (STARTUP,
1984).  The characteristic of the ocular secretion was
not influenced by the topic use of cyclosporine A,
which presents specific immunosupressing action on
T lymphocytes, and did not interfere in the innate
immune response by phagocytic cells (DIASIO &
LOBUGLIO, 1996), what explains its uncommon
association with opportunistic infections (RYFFEL,
1989).
Figure 2 – A) Control cornea at day 30: epithelial edema, vessels into the implant and stroma, the pericardium is incorporated. To the
stroma, new collagen fibers between the epithelium and implant; monuclear cells infiltrate predominates (H&E X 200); B)
Treated cornea at day 30:re-epithelization, epithelial edema, heavy vascularization with large vessels, pericardium
incorporated to the stroma (H&E X 200).
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In relation to the cicatricial process,
epithelial repair was quick, and characterized by sliding
and mitosis of epithelial cells in a centripetal direction
(PEIFFER JR. et al., 1999). Acanthosis observed in the
extremities of the implant in this study confirms the
mitotic capacity of these cells (PEIFFER JR. et al., 1999).
The repair of the stroma occurs more slowly, through
fibroblastic proliferation. In the final phase, fibroblastic
tissue decreases and collagenous fibers are
reorganized in a parallel fashion, determining the
intensity of the scar and the subsequent transparency
of the cornea. This was observed in the later periods
of evolution, with the bilateral incorporation of equine
pericardium to the corneal stroma. Complete and
bilateral repithelization on the 3rd postoperative day
confirms that cyclosporine A does not present adverse
effects on the epithelium, during the cicatricial  process
in the cornea (BEHRENS-BAUMAN et al., 1986; BELIN
et al., 1990).
Edema is the main responsible factor for
the loss of corneal transparency (PEIFFER JR. et al.,
1999) and thin vesicles are found when it affects the
epithelium. When affecting the stroma, it produces
diffuse mist, and is characterized by an increase in
cornea thickness (SPENCER, 1996); this was bilaterally
observed on day 15 and 30.
The degree of opacification is not only
associated with the edema, but also to the number and
concentration of inflammatory cells, to the presence
or absence of neovessels and to enzyme-induced
stroma necrosis (SPENCER, 1996). This may explain
the higher intensity of cornea opacification on days
15 and 30, when intense vascularization and important
inflammatory infiltrates occurred, mainly in the treated
cornea.
 In relation to vascular phenomena,
vascularization was observed bilaterally on the 3rd
postoperative day. This may be asscociated with the
hypothesis that angiogenic factors or cytokines are
released in the first hours after the surgical procedure
(NAUMANN & SAUTTER, 1988; KOCH, 1992) with
vessels in the cornea 2 to 4 days after the loss of
epithelium and stroma (PEIFFER JR. et al., 1999).
Corneal vascularization favors the cicatricial
process, including tissue remodeling (EPSTEIN et al,
1987). On the other hand, it is not desirable due to the
loss of corneal  transparency (PEIFFER JR. et al., 1999).
Several trials have been performed in order to evaluate
aspects related to corneal vascularization
(SUNDERKOTTTER et al., 1991a; REHANY &
WAISMAN, 1994; KENYON et al., 1996; BENELLI et
al., 1997; BARROS et al., 2000) and  several therapeutic
schemes were attempted in order to decrease or inhibit
it, mainly the topic or systemic administration of
cyclosporine A at different concentrations (LIPMAN
et al., 1992; REHANY & WAISMAN, 1994; BENELLI
et al., 1997).
   Cyclosporine A is a cyclic polypeptide
from the fungus Tolypocladium inflatum Gans, and
presents the ability to inhibit the activation and
proliferation of T-helper lymphocytes, by blocking the
release of lymphokines (DIASIO & LOBUGLIO, 1996).
It was successfully used in topic treatment, decreasing
the neovascularization in the cornea of dogs
presenting keratoconjunctivitis sicca (KASWAN et
al., 1989). It also reduced corneal vascularization that
developed in mice after an intracorneal injection of
interleukin-2, when intramuscularly administered
(LIPMAN et al., 1992). Ciclosporine A given
subcutaneously also has been found to supress new
vessel formation induced in the mesenteric-window
assay in rats (NORRBY, 1992). It also is reported to
produce clinical improvement in psoriasis and certain
epithelial neoplasms in which angiogenesis is
proeminent (NORRBY, 1992). It decreased the growth
of vessels in the cornea of rats after xenotransplantation
and chemical cauterization using silver nitrate, when a
4% solution was topically and systematically
administered. However, it was not effective in the
blockage of new vessels growth induced by the
insertion of an angiogenic disc in the subcutaneous
tissue, when systematically or intradisc administered
(BENELLI et al., 1997).
Topical administration of cyclosporine A
does not produce a measurable systemic concentration
or contralateral ocular immunusupression (FOETS et
al., 1985; BELIN et al., 1990; JACKSON et al., 1991;
BENELLI et al., 1997; STEVENSON et al., 2000) enabling
each animal to be its own control (JACKSON et al.,
1991).
Cyclosporine A 2% did not inhibit or
decrease the formation of vessels in this trial, although
it may have showed anti-angiogenic or angiostatic
activity in other studies (LIPMAN et al., 1992;
NORRBY, 1992; BENELLI et al., 1997). The mechanisms
by which cyclosporine A reduces or inhibits
angiogenesis in some, but not in all models, remain
unrecognized (BENELLI et al., 1997).  One of the
hypothesis is that it may be related to the nature and
the permanence of the injury; to the quality and time
of the surgical procedure and to the kind of suture
used (NASISSE, 1985; KERN, 1990). Therefore, the
angiogenic response may vary significantly according
to these characteristics, to  the species involved, to
the type of biological membrane used and to its
particular angiogenic ability (BARROS et al., 2000).
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Cyclosporine A inhibits only the
transcription of the genes for interleukin-2  (IL-2) and
interleukin-4 (IL-4) (RIZZO, personal communication,
2000). Thus, the other lymphokines (DIASIO &
LOBUGLIO, 1996; ROOK & BALKWILL, 1999;
GOLDSBY, 2000a)  may produce angiogenic effects,
what could explain the similarity between the control
and treated corneas  on the 3rd, 7th and 60th
postoperative day. Cyclosporine A also increases the
expression of TGF-β, (PRASHAR et al., 1995; KHANNA
et al., 1997; SHIN et al., 1998)  which presents evident
angiogenic effects (ROBERTS et al., 1986;
SUNDERKOTTER et al., 1991b).
It is important to note that, during the
cicatricial process, epithelial cells, keratocytes and
stromal fibroblasts may also synthesize and release
growth factors with angiogenic activity (SWANK &
HOSGOOD, 1996).
As it is know that several cells take part in
the angiogenesis phenomenon, and although
lymphocytes are relevant in this process, macrophages
are also very important due to their intense secretion
of factors that may be directly or indirectly angiogenic,
contributing with more than one factor at each stage
of the angiogenesis (POLVERINI et al., 1977), what
may compensate for the angiogenic effects of the
lymphokines blocked by cyclosporine A.
The occurrence of a more intense
vascularization process on days 15 and 30 in the
corneas treated with cyclosporine A 2% may be due
to the combined action of the angiogenic cytokines
secreted by macrophages and those released by the
lymphocytes and not affected by cyclosporine,
together with the increase of TGF-β expression
(PRASHAR et al., 1995; KHANNA et al., 1997; SHIN
et al., 1998). Another possibility is that, because of
the inhibition of the synthesis and release of IL-2 and
IL-4, and of the increase of TGF-β expression, both
caused by cyclosporine A, there would be an
unbalance between angiogenic and anti-angiogenic
factors. This balance is extremely important for the
control of angiogenesis, which is dose-dependent
(STRIETER et al., 1992). Therefore, it may  affect the
secretory pattern of lymphocytes and macrophages,
what would result in the increase in angiogenic
cytokine release by these cells.
In relation to the inflammatory reaction, cell
infiltrate was characterized by the invasion of the site
with polymorphonuclear and mononuclear
lymphocytes. Neutrophils were the most prevalent in
the beginning of the inflammatory process, followed
by monocytes and lymphocytes that also migrated to
the site of injury. The early inflammatory cell infiltrated
is considered a pre-requisite for angiogenesis
induction (SUNDERKOTTER et al., 1991a), for it acts
in the degradation of proteins from the extracellular
matrix and would justify the beginning of the
vascularization process as early as the 3rd
postoperative day, bilaterally.
An important stage in leukocyte migration
is the fixation of the cells to the vascular endothelium,
as a consequence of the interaction between the
molecules on the membranes of the leukocytes with
the corresponding molecules on the activated
endothelium (SPENCER, 1996), controled by the
expression of the adhesion molecule E-selectin on the
surface of the endothelium (KOCH et al., 1995). It has
recently been suggested that  this molecule presents
direct angiogenic effect on the endothelial cells (KOCH
et al., 1995) and that cyclosporine A may promote the
low regulation of the expression of this molecule by
the vascular endothelium, what would suppress the
growth of vessels (BENELLI et al., 1997). In the present
trial, however, inflammatory cell infiltrate was observed
as early as the 3rd postoperative day, and was bilaterally
evident up to day 60. This would confirm that
cyclosporine A did not present any effect on this
adhesion molecule. It is important to emphasize that
cytokines TNF-α and IL-1, which stimulate the
secretion of E-selectin by the endothelium (KOCH et
al., 1995; GOLDSBY, 2000b) are not affected by
cyclosporine A.
CONCLUSIONS
Lamellar keratectomy with equine
pericardium graft preserved in 98% glycerin  was a
feasible model for the study of inflammation kinetics
and angiogenesis phenomenon in the cicatricial
reaction of the cornea. There was intense
vascularization and an important fibroblast response,
with the permanence of cicatricial leucoma and corneal
vessels on the 60th postoperative day.
Cyclosporine A 2% did not interfere in the
corneal cicatricial process generated by keratoplasty
with lamellar equine pericardium graft. It also did not
decrease the corneal vascularization process in this
study.
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